CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone

por Wasan, H S, Springett, G M, Chodkiewicz, C, Wong, R, Maurel, J, Barone, C, Rosbrook, B, Ricart, A D, Kim, S, Spano, J-P
Publicado 2009